Chronic Pain Rehabilitation in Patients With Small Fiber Neuropathy
Launched by ACADEMISCH ZIEKENHUIS MAASTRICHT · Mar 22, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how rehabilitation programs can help people with small fiber neuropathy (SFN), a condition that causes ongoing nerve pain. Many treatments for this type of pain don't work well, and patients often struggle with both physical and psychological challenges related to their pain. The trial will test a rehabilitation approach that includes education about pain, cognitive behavioral therapy (which helps change negative thoughts and behaviors), and activities designed to gradually increase physical movement. This is important because there are currently no specific rehabilitation programs available for SFN patients.
To participate in this study, you need to be over 18 years old and have been diagnosed with idiopathic small fiber neuropathy through a skin biopsy. People who have other health conditions that could cause similar symptoms or those who have recently received certain therapies will not be eligible. If you join, you can expect to engage in a structured program aimed at improving your pain management and overall well-being. This trial is open to all genders, and it’s a great opportunity for those looking for new ways to manage their chronic pain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged older than 18 years,
- • Skin-biopsy proven idiopathic small fiber neuropathy (SFN),
- • Main goal/purpose to achieve with rehabilitation therapy.
- Exclusion Criteria:
- • Are not able to provide written informed consent,
- • Have an underlying condition of SFN (diabetes, SCN (sodium voltage-gated channel alpha) 9A (subunit 9A) /10A (subunit 10A) /11A (subunit 11A) mutation, hypothyroidism, renal failure, vitamin B12 deficiency, monoclonal gammopathy of undetermined significance, alcohol abuses, malignancies, chemotherapeutic drugs),
- • Have other neurological disease than SFN that may cause pain in the feet and/or damage to the somatosensory nervous system, are excluded,
- • Have received any form of cognitive behavioral therapy within the last 6 months will be excluded from this study,
- • Have insufficient comprehension of the Dutch language.
About Academisch Ziekenhuis Maastricht
Academisch Ziekenhuis Maastricht (AZM) is a leading academic medical center located in Maastricht, Netherlands, dedicated to advancing healthcare through innovative research and patient-centered care. As a prominent institution in the field of clinical trials, AZM integrates cutting-edge scientific research with clinical practice, fostering collaborations across disciplines to enhance therapeutic options and improve patient outcomes. With a commitment to high ethical standards and regulatory compliance, AZM actively engages in a diverse range of clinical studies, contributing to the global body of medical knowledge while ensuring the highest quality of care for its patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, , Netherlands
Maastricht, Limburg, Netherlands
Patients applied
Trial Officials
J. AC Verbunt, MD, PhD
Principal Investigator
Adelante Zorggroep
J. GJ Hoeijmakers, MD, PhD
Principal Investigator
Maastricht University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials